Metabolism addiction in pancreatic cancer

Cell Death and Disease

Volumn 5, Issue 2, 2014, Pages

  Blum, R ^a   Kloog, Y ^b  

^a NEW YORK UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b TEL AVIV UNIVERSITY   (Israel)

Author keywords

glutamine metabolism; glycolysis; metabolism; oncogenic Ras; pancreatic cancer; pentose phosphate pathway

Indexed keywords

FATTY ACID; GLUTAMINE; RAS PROTEIN; SALIRASIB;

ARTICLE; AUTOPHAGY; CANCER MORTALITY; ENZYME METABOLISM; FATTY ACID METABOLISM; GENE MUTATION; GLYCOLYSIS; HUMAN; LIPID METABOLISM; METABOLISM; NONHUMAN; PANCREAS ADENOCARCINOMA; PENTOSE PHOSPHATE CYCLE; PRIORITY JOURNAL; PROTEIN METABOLISM; SIGNAL TRANSDUCTION; TUMOR CELL; TUMOR GROWTH; TUMOR MICROENVIRONMENT;

ANIMALS; ANTINEOPLASTIC AGENTS; CARCINOMA, PANCREATIC DUCTAL; DRUG DESIGN; ENERGY METABOLISM; GENETIC PREDISPOSITION TO DISEASE; HUMANS; MOLECULAR TARGETED THERAPY; PANCREATIC NEOPLASMS; PHENOTYPE; PROGNOSIS; SIGNAL TRANSDUCTION;

EID: 84896778081     PISSN: None     EISSN: 20414889     Source Type: Journal    
DOI: 10.1038/cddis.2014.38     Document Type: Article

References (170)

1. Jemal A, Murray T, Ward E, Samuels A, Tiwari RC, Ghafoor A et al. Cancer statistics, 2005. CA Cancer J Clin 2005; 55: 10-30.
2. Parkin DM, Bray FI, Devesa SS. Cancer burden in the year 2000. The global picture. Eur J Cancer 2001; 37(Suppl 8): S4-66.
3. Pan S, Chen R, Brand RE, Hawley S, Tamura Y, Gafken PR et al. Multiplex targeted proteomic assay for biomarker detection in plasma: A pancreatic cancer biomarker case study. J Proteome Res 2012; 11: 1937-1948.
4. Hocker JR, Mohammed A, Aston CE, Brewer M, Lightfoot SA, Rao CV et al. Mass profiling of serum to distinguish mice with pancreatic cancer induced by a transgenic kras mutation. Int J Cancer 2013; 133: 2662-2671.
5. Li A, Yu J, Kim H, Wolfgang CL, Canto M, Hruban RH et al. MicroRNA array analysis finds elevated serum miR-1290 accurately distinguishes patients with low-stage pancreatic cancer from healthy and disease controls. Clin Cancer Res 2013; 19: 3600-3610.
6. Ren C, Chen H, Han C, Jin G, Wang D, Tang D. Detection and molecular analysis of circulating tumor cells for early diagnosis of pancreatic cancer. Med Hypotheses 2013; 80: 833-836.
7. Moore MJ, Goldstein D, Hamm J, Figer A, Hecht JR, Gallinger S et al. Erlotinib plus gemcitabine compared with gemcitabine alone in patients with advanced pancreatic cancer: A phase III trial of the National Cancer Institute of Canada Clinical Trials Group. J Clin Oncol 2007; 25: 1960-1966.
8. Kulke MH, Blaszkowsky LS, Ryan DP, Clark JW, Meyerhardt JA, Zhu AX et al. Capecitabine plus erlotinib in gemcitabine-refractory advanced pancreatic cancer. J Clin Oncol 2007; 25: 4787-4792.
9. Quispe-Tintaya W, Chandra D, Jahangir A, Harris M, Casadevall A, Dadachova E et al. Nontoxic radioactive Listeriaat is a highly effective therapy against metastatic pancreatic cancer. Proc Natl Acad Sci USA 2013; 110: 8668-8673.
10. Conroy T, Gavoille C, Adenis A. Metastatic pancreatic cancer: Old drugs, new paradigms. Curr Opin Oncol 2011; 23: 390-395.
11. Muller SA, Tarantino I, Martin DJ, Schmied BM. Pancreatic surgery: Beyond the traditional limits. Recent Results Cancer Res 2012; 196: 53-64.
12. Poruk KE, Firpo MA, Adler DG, Mulvihill SJ. Screening for pancreatic cancer: Why, how, and whö Ann Surg 2013; 257: 17-26.
13. Wray CJ, Ahmad SA, Matthews JB, Lowy AM. Surgery for pancreatic cancer: Recent controversies and current practice. Gastroenterology 2005; 128: 1626-1641.
14. Reddy S, Wolfgang CL. The role of surgery in the management of isolated metastases to the pancreas. Lancet Oncol 2009; 10: 287-293.
15. Cleary SP, Gryfe R, Guindi M, Greig P, Smith L, Mackenzie R et al. Prognostic factors in resected pancreatic adenocarcinoma: Analysis of actual 5-year survivors. J Am Coll Surg 2004; 198: 722-731.
16. Klein AP, Brune KA, Petersen GM, Goggins M, Tersmette AC, Offerhaus GJ et al. Prospective risk of pancreatic cancer in familial pancreatic cancer kindreds. Cancer Res 2004; 64: 2634-2638.
17. Brune KA, Lau B, Palmisano E, Canto M, Goggins MG, Hruban RH et al. Importance of age of onset in pancreatic cancer kindreds. J Natl Cancer Inst 2010; 102: 119-126.
18. Klein AP, Hruban RH, Brune KA, Petersen GM, Goggins M. Familial pancreatic cancer. Cancer J 2001; 7: 266-273.
19. van der Heijden MS, Yeo CJ, Hruban RH, Kern SE. Fanconi anemia gene mutations in young-onset pancreatic cancer. Cancer Res 2003; 63: 2585-2588.
20. Goggins M, Schutte M, Lu J, Moskaluk CA, Weinstein CL, Petersen GM et al. Germline BRCA2 gene mutations in patients with apparently sporadic pancreatic carcinomas. Cancer Res 1996; 56: 5360-5364.
21. Jones S, Hruban RH, Kamiyama M, Borges M, Zhang X, Parsons DW et al. Exomic sequencing identifies PALB2 as a pancreatic cancer susceptibility gene. Science 2009; 324: 217.
22. Roberts NJ, Jiao Y, Yu J, Kopelovich L, Petersen GM, Bondy ML et al. ATM mutations in patients with hereditary pancreatic cancer. Cancer Discov 2012; 2: 41-46.
23. Ryu B, Jones J, Blades NJ, Parmigiani G, Hollingsworth MA, Hruban RH et al. Relationships and differentially expressed genes among pancreatic cancers examined by large-scale serial analysis of gene expression. Cancer Res 2002; 62: 819-826.
24. Iacobuzio-Donahue CA, Maitra A, Shen-Ong GL, van Heek T, Ashfaq R, Meyer R et al. Discovery of novel tumor markers of pancreatic cancer using global gene expression technology. Am J Pathol 2002; 160: 1239-1249.
25. Hidalgo M. Pancreatic cancer. N Engl J Med 2010; 362: 1605-1617.
26. Weinstein IB. Disorders in cell circuitry during multistage carcinogenesis: The role of homeostasis. Carcinogenesis 2000; 21: 857-864.
27. Dang CV. Links between metabolism and cancer. Genes Dev 2012; 26: 877-890.
28. Weinstein IB, Joe A. Oncogene addiction. Cancer Res 2008; 68: 3077-3080; discussion 3080.
29. Warburg O, Wind F, Negelein E. The metabolism of tumors in the body. J Gen Physiol 1927; 8: 519-530.
30. Brahimi-Horn MC, Chiche J, Pouyssegur J. Hypoxia signalling controls metabolic demand. Curr Opin Cell Biol 2007; 19: 223-229.
31. Warburg O. On the origin of cancer cells. Science 1956; 123: 309-314.
32. Kroemer G, Pouyssegur J. Tumor cell metabolism: Cancer's Achilles' heel. Cancer Cell 2008; 13: 472-482.
33. Guillaumond F, Leca J, Olivares O, Lavaut MN, Vidal N, Berthezene P et al. Strengthened glycolysis under hypoxia supports tumor symbiosis and hexosamine biosynthesis in pancreatic adenocarcinoma. Proc Natl Acad Sci USA 2013; 110: 3919-3924.
34. Rong Y, Wu W, Ni X, Kuang T, Jin D, Wang D et al. Lactate dehydrogenase A is overexpressed in pancreatic cancer and promotes the growth of pancreatic cancer cells. Tumour Biol 2013; 34: 1523-1530.
35. Zhou W, Capello M, Fredolini C, Racanicchi L, Piemonti L, Liotta LA et al. Proteomic analysis reveals Warburg effect and anomalous metabolism of glutamine in pancreatic cancer cells. J Proteome Res 2012; 11: 554-563.
36. Mikuriya K, Kuramitsu Y, Ryozawa S, Fujimoto M, Mori S, Oka M et al. Expression of glycolytic enzymes is increased in pancreatic cancerous tissues as evidenced by proteomic profiling by two-dimensional electrophoresis and liquid chromatography-mass spectrometry/mass spectrometry. Int J Oncol 2007; 30: 849-855.
37. Ishihara H, Wang H, Drewes LR, Wollheim CB. Overexpression of monocarboxylate transporter and lactate dehydrogenase alters insulin secretory responses to pyruvate and lactate in beta cells. J Clin Invest 1999; 104: 1621-1629.
38. Zhou W, Capello M, Fredolini C, Piemonti L, Liotta LA, Novelli F et al. Proteomic analysis of pancreatic ductal adenocarcinoma cells reveals metabolic alterations. J Proteome Res 2011; 10: 1944-1952.
39. Akakura N, Kobayashi M, Horiuchi I, Suzuki A, Wang J, Chen J et al. Constitutive expression of hypoxia-inducible factor-1alpha renders pancreatic cancer cells resistant to apoptosis induced by hypoxia and nutrient deprivation. Cancer Res 2001; 61: 6548-6554.
40. Permert J, Ihse I, Jorfeldt L, von Schenck H, Arnqvist HJ, Larsson J. Pancreatic cancer is associated with impaired glucose metabolism. Eur J Surg 1993; 159: 101-107.
41. Liu Z, Jia X, Duan Y, Xiao H, Sundqvist KG, Permert J et al. Excess glucose induces hypoxia-inducible factor-1alpha in pancreatic cancer cells and stimulates glucose metabolism and cell migration. Cancer Biol Ther 2013; 14: 428-435.
42. Pouyssegur J, Dayan F, Mazure NM. Hypoxia signalling in cancer and approaches to enforce tumour regression. Nature 2006; 441: 437-443.
43. Koukourakis MI, Giatromanolaki A, Harris AL, Sivridis E. Comparison of metabolic pathways between cancer cells and stromal cells in colorectal carcinomas: A metabolic survival role for tumor-Associated stroma. Cancer Res 2006; 66: 632-637.
44. Ota S, Geschwind JF, Buijs M, Wijlemans JW, Kwak BK, Ganapathy-Kanniappan S. Ultrasound-guided direct delivery of 3-bromopyruvate blocks tumor progression in an orthotopic mouse model of human pancreatic cancer. Target Oncol 2013; 8: 145-151.
45. Fischer K, Hoffmann P, Voelkl S, Meidenbauer N, Ammer J, Edinger M et al. Inhibitory effect of tumor cell-derived lactic acid on human T cells. Blood 2007; 109: 3812-3819.
46. Amedei A, Niccolai E, Benagiano M, Della Bella C, Cianchi F, Bechi P et al. Ex vivo analysis of pancreatic cancer-infiltrating T lymphocytes reveals that ENO-specific Tregs accumulate in tumor tissue and inhibit Th1/Th17 effector cell functions. Cancer Immunol Immunother 2013; 62: 1249-1260.
47. Lunt SY, Vander Heiden MG. Aerobic glycolysis: Meeting the metabolic requirements of cell proliferation. Annu Rev Cell Dev Biol 2011; 27: 441-464.
48. Witkiewicz AK, Nguyen KH, Dasgupta A, Kennedy EP, Yeo CJ, Lisanti MP et al. Co-expression of fatty acid synthase and caveolin-1 in pancreatic ductal adenocarcinoma: Implications for tumor progression and clinical outcome. Cell Cycle 2008; 7: 3021-3025.
49. Yang Y, Liu H, Li Z, Zhao Z, Yip-Schneider M, Fan Q et al. Role of fatty acid synthase in gemcitabine and radiation resistance of pancreatic cancers. Int J Biochem Mol Biol 2011; 2: 89-98.
50. Liu L, Gong L, Zhang Y, Li N. Glycolysis in Panc-1 human pancreatic cancer cells is inhibited by everolimus. Exp Ther Med 2013; 5: 338-342.
51. Seidler NW. Compartmentation of GAPDH. Adv Exp Med Biol 2013; 985: 61-101.
52. Le A, Cooper CR, Gouw AM, Dinavahi R, Maitra A, Deck LM et al. Inhibition of lactate dehydrogenase A induces oxidative stress and inhibits tumor progression. Proc Natl Acad Sci USA 2010; 107: 2037-2042.
53. Blum R, Jacob-Hirsch J, Amariglio N, Rechavi G, Kloog Y. Ras inhibition in glioblastoma down-regulates hypoxia-inducible factor-1alpha, causing glycolysis shutdown and cell death. Cancer Res 2005; 65: 999-1006.
54. Blum R, Elkon R, Yaari S, Zundelevich A, Jacob-Hirsch J, Rechavi G et al. Gene expression signature of human cancer cell lines treated with the ras inhibitor salirasib (S-farnesylthiosalicylic acid). Cancer Res 2007; 67: 3320-3328.
55. Blum R, Jacob-Hirsch J, Rechavi G, Kloog Y. Suppression of survivin expression in glioblastoma cells by the Ras inhibitor farnesylthiosalicylic acid promotes caspasedependent apoptosis. Mol Cancer Ther 2006; 5: 2337-2347.
56. Riganti C, Gazzano E, Polimeni M, Aldieri E, Ghigo D. The pentose phosphate pathway: An antioxidant defense and a crossroad in tumor cell fate. Free Radical Biol Med 2012; 53: 421-436.
57. Cairns RA, Harris IS, Mak TW. Regulation of cancer cell metabolism. Nat Rev Cancer 2011; 11: 85-95.
58. Nagaoka Y, Iuchi Y, Ikeda Y, Fujii J. Glutathione reductase is expressed at high levels in pancreatic islet cells. Redox Rep 2004; 9: 321-324.
59. Dashty M. A quick look at biochemistry: Carbohydrate metabolism. Clin Biochem 2013; 46: 1339-1352.
60. Ying H, Kimmelman AC, Lyssiotis CA, Hua S, Chu GC, Fletcher-Sananikone E et al. Oncogenic Kras maintains pancreatic tumors through regulation of anabolic glucose metabolism. Cell 2012; 149: 656-670.
61. Bar-Sagi DA. Ras by any other name. Mol Cell Biol 2001; 21: 1441-1443.
62. Blum R, Kloog Y. Tailoring Ras-pathway-inhibitor combinations for cancer therapy. Drug Resistance Updates 2005; 8: 369-380.
63. Blum R, Cox AD, Kloog Y. Inhibitors of chronically active ras: Potential for treatment of human malignancies. Recent Patents Anti-Cancer Drug Discovery 2008; 3: 31-47.
64. Tada M, Omata M, Kawai S, Saisho H, Ohto M, Saiki RK et al. Detection of ras gene mutations in pancreatic juice and peripheral blood of patients with pancreatic adenocarcinoma. Cancer Res 1993; 53: 2472-2474.
65. Yamada T, Nakamori S, Ohzato H, Oshima S, Aoki T, Higaki N et al. Detection of K-ras gene mutations in plasma DNA of patients with pancreatic adenocarcinoma: Correlation with clinicopathological features. Clin Cancer Res 1998; 4: 1527-1532.
66. Hingorani SR, Petricoin EF, Maitra A, Rajapakse V, King C, Jacobetz MA et al. Preinvasive and invasive ductal pancreatic cancer and its early detection in the mouse. Cancer Cell 2003; 4: 437-450.
67. Qian J, Niu J, Li M, Chiao PJ, Tsao MS. In vitro modeling of human pancreatic duct epithelial cell transformation defines gene expression changes induced by K-ras oncogenic activation in pancreatic carcinogenesis. Cancer Res 2005; 65: 5045-5053.
68. Mohamedali A, Lea NC, Feakins RM, Raj K, Mufti GJ, Kocher HM. AKT1 (E17K) mutation in pancreatic cancer. Tech Cancer Res Treatment 2008; 7: 407-408.
69. Okami K,Wu L, Riggins G, Cairns P, Goggins M, Evron E et al. Analysis of PTEN/MMAC1 alterations in aerodigestive tract tumors. Cancer Res 1998; 58: 509-511.
70. Sakurada A, Suzuki A, Sato M, Yamakawa H, Orikasa K, Uyeno S et al. Infrequent genetic alterations of the PTEN/MMAC1 gene in Japanese patients with primary cancers of the breast, lung, pancreas, kidney, and ovary. Jpn J Cancer Res 1997; 88: 1025-1028.
71. Rajagopalan H, Bardelli A, Lengauer C, Kinzler KW, Vogelstein B, Velculescu VE. Tumorigenesis: RAF/RAS oncogenes and mismatch-repair status. Nature 2002; 418: 934.
72. Davies H, Bignell GR, Cox C, Stephens P, Edkins S, Clegg S et al. Mutations of the BRAF gene in human cancer. Nature 2002; 417: 949-954.
73. Berger DH, Jardines LA, Chang H, Ruggeri B. Activation of Raf-1 in human pancreatic adenocarcinoma. J Surg Res 1997; 69: 199-204.
74. Calhoun ES, Jones JB, Ashfaq R, Adsay V, Baker SJ, Valentine V et al. BRAF and FBXW7 (CDC4, FBW7, AGO, SEL10) mutations in distinct subsets of pancreatic cancer: Potential therapeutic targets. Am J Pathol 2003; 163: 1255-1260.
75. Schonleben F, Qiu W, Ciau NT, Ho DJ, Li X, Allendorf JD et al. PIK3CA mutations in intraductal papillary mucinous neoplasm/carcinoma of the pancreas. Clin Cancer Res 2006; 12: 3851-3855.
76. Asano T, Yao Y, Zhu J, Li D, Abbruzzese JL, Reddy SA. The PI 3-kinase/Akt signaling pathway is activated due to aberrant Pten expression and targets transcription factors NF-kappaB and c-Myc in pancreatic cancer cells. Oncogene 2004; 23: 8571-8580.
77. Altomare DA, Tanno S, De Rienzo A, Klein-Szanto AJ, Skele KL, Hoffman JP et al. Frequent activation of AKT2 kinase in human pancreatic carcinomas. J Cell Biochem 2002; 87: 470-476.
78. Cheng JQ, Ruggeri B, Klein WM, Sonoda G, Altomare DA, Watson DK et al. Amplification of AKT2 in human pancreatic cells and inhibition of AKT2 expression and tumorigenicity by antisense RNA. Proc Natl Acad Sci USA 1996; 93: 3636-3641.
79. Ruggeri BA, Huang L, Wood M, Cheng JQ, Testa Jr. Amplification and overexpression of the AKT2 oncogene in a subset of human pancreatic ductal adenocarcinomas. Mol Carcinog 1998; 21: 81-86.
80. Schlieman MG, Fahy BN, Ramsamooj R, Beckett L, Bold RJ. Incidence, mechanism and prognostic value of activated AKT in pancreas cancer. Br J Cancer 2003; 89: 2110-2115.
81. Yamamoto S, Tomita Y, Hoshida Y, Morooka T, Nagano H, Dono K et al. Prognostic significance of activated Akt expression in pancreatic ductal adenocarcinoma. Clin Cancer Res 2004; 10: 2846-2850.
82. Barthel A, Okino ST, Liao J, Nakatani K, Li J, Whitlock Jr. JP et al. Regulation of GLUT1 gene transcription by the serine/threonine kinase Akt1. J Biol Chem 1999; 274: 20281-20286.
83. Deprez J, Vertommen D, Alessi DR, Hue L, Rider MH. Phosphorylation and activation of heart 6-phosphofructo-2-kinase by protein kinase B and other protein kinases of the insulin signaling cascades. J Biol Chem 1997; 272: 17269-17275.
84. Robey RB, Hay N. Mitochondrial hexokinases, novel mediators of the antiapoptotic effects of growth factors and Akt. Oncogene 2006; 25: 4683-4696.
85. Gottlob K, Majewski N, Kennedy S, Kandel E, Robey RB, Hay N. Inhibition of early apoptotic events by Akt/PKB is dependent on the first committed step of glycolysis and mitochondrial hexokinase. Genes Dev 2001; 15: 1406-1418.
86. Sodhi A, Montaner S, Miyazaki H, Gutkind JS. MAPK and Akt act cooperatively but independently on hypoxia inducible factor-1alpha in rasV12 upregulation of VEGF. Biochem Biophys Res Commun 2001; 287: 292-300.
87. Hu Y, Lu W, Chen G, Wang P, Chen Z, Zhou Y et al. K-ras(G12V) transformation leads to mitochondrial dysfunction and a metabolic switch from oxidative phosphorylation to glycolysis. Cell Res 2012; 22: 399-412.
88. Mazure NM, Chen EY, Laderoute KR, Giaccia AJ. Induction of vascular endothelial growth factor by hypoxia is modulated by a phosphatidylinositol 3-kinase/Akt signaling pathway in Ha-ras-Transformed cells through a hypoxia inducible factor-1 transcriptional element. Blood 1997; 90: 3322-3331.
89. Gao N, Ding M, Zheng JZ, Zhang Z, Leonard SS, Liu KJ et al. Vanadate-induced expression of hypoxia-inducible factor 1 alpha and vascular endothelial growth factor through phosphatidylinositol 3-kinase/Akt pathway and reactive oxygen species. J Biol Chem 2002; 277: 31963-31971.
90. Fukuda R, Hirota K, Fan F, Jung YD, Ellis LM, Semenza GL. Insulin-like growth factor 1 induces hypoxia-inducible factor 1-mediated vascular endothelial growth factor expression, which is dependent on MAP kinase and phosphatidylinositol 3-kinase signaling in colon cancer cells. J Biol Chem 2002; 277: 38205-38211.
91. Mottet D, Michel G, Renard P, Ninane N, Raes M, Michiels C. Role of ERK and calcium in the hypoxia-induced activation of HIF-1. J Cell Physiol 2003; 194: 30-44.
92. Jansen B, Schlagbauer-Wadl H, Kahr H, Heere-Ress E, Mayer BX, Eichler H et al. Novel Ras antagonist blocks human melanoma growth. Proc Natl Acad Sci USA 1999; 96: 14019-14024.
93. Jansen B, Heere-Ress E, Schlagbauer-Wadl H, Halaschek-Wiener J, Waltering S, Moll I et al. Farnesylthiosalicylic acid inhibits the growth of human Merkel cell carcinoma in SCID mice. J Mol Med (Berl) 1999; 77: 792-797.
94. Erlich S, Tal-Or P, Liebling R, Blum R, Karunagaran D, Kloog Y et al. Ras inhibition results in growth arrest and death of androgen-dependent and androgen-independent prostate cancer cells. Biochem Pharmacol 2006; 72: 427-436.
95. Laheru D, Shah P, Rajeshkumar NV, McAllister F, Taylor G, Goldsweig H et al. Integrated preclinical and clinical development of S-Trans, trans-Farnesylthiosalicylic acid (FTS, Salirasib) in pancreatic cancer. Invest New Drugs 2012; 30: 2391-2399.
96. Haklai R, Elad-Sfadia G, Egozi Y, Kloog Y. Orally administered FTS (salirasib) inhibits human pancreatic tumor growth in nude mice. Cancer Chemother Pharmacol 2008; 61: 89-96.
97. Weisz B, Giehl K, Gana-Weisz M, Egozi Y, Ben-Baruch G, Marciano D et al. A new functional Ras antagonist inhibits human pancreatic tumor growth in nude mice. Oncogene 1999; 18: 2579-2588.
98. Maher JC, Krishan A, Lampidis TJ. Greater cell cycle inhibition and cytotoxicity induced by 2-deoxy-D-glucose in tumor cells treated under hypoxic versus aerobic conditions. Cancer Chemother Pharmacol 2004; 53: 116-122.
99. Xiao H, Li S, Zhang D, Liu T, Yu M, Wang F. Separate and concurrent use of 2-deoxy-Dglucose and 3-bromopyruvate in pancreatic cancer cells. Oncol Rep 2013; 29: 329-334.
100. Goldberg L, Ocherashvilli A, Daniels D, Last D, Cohen ZR, Tamar G et al. Salirasib (farnesyl thiosalicylic acid) for brain tumor treatment: A convection-enhanced drug delivery study in rats. Mol Cancer Ther 2008; 7: 3609-3616.
101. Dearling JL, Flynn AA, Sutcliffe-Goulden J, Petrie IA, Boden R, Green AJ et al. Analysis of the regional uptake of radiolabeled deoxyglucose analogs in human tumor xenografts. J Nucl Med 2004; 45: 101-107.
102. Ben Sahra I, Laurent K, Giuliano S, Larbret F, Ponzio G, Gounon P et al. Targeting cancer cell metabolism: The combination of metformin and 2-deoxyglucose induces p53-dependent apoptosis in prostate cancer cells. Cancer Res 2010; 70: 2465-2475.
103. Goldberg L, Israeli R, Kloog Y. FTS and 2-DG induce pancreatic cancer cell death and tumor shrinkage in mice. Cell Death Dis 2012; 3: E284.
104. DeBerardinis RJ, Lum JJ, Hatzivassiliou G, Thompson CB. The biology of cancer: Metabolic reprogramming fuels cell growth and proliferation. Cell Metab 2008; 7: 11-20.
105. Vander Heiden MG, Cantley LC, Thompson CB. Understanding the Warburg effect: The metabolic requirements of cell proliferation. Science 2009; 324: 1029-1033.
106. Wise DR, Thompson CB. Glutamine addiction: A new therapeutic target in cancer. Trends Biochem Sci 2010; 35: 427-433.
107. Owen OE, Kalhan SC, Hanson RW. The key role of anaplerosis and cataplerosis for citric acid cycle function. J Biol Chem 2002; 277: 30409-30412.
108. Young VR, Ajami AM. Glutamine: The emperor or his clothes? J Nutr 2001; 131(9 Suppl): 2449S-2459S; discussion 2486S-2447S.
109. Erickson JW, Cerione RA. Glutaminase: A hot spot for regulation of cancer cell metabolism? Oncotarget 2010; 1: 734-740.
110. Shanware NP, Mullen AR, DeBerardinis RJ, Abraham RT. Glutamine: Pleiotropic roles in tumor growth and stress resistance. J Mol Med (Berl) 2011; 89: 229-236.
111. Son J, Lyssiotis CA, Ying H, Wang X, Hua S, Ligorio M et al. Glutamine supports pancreatic cancer growth through a KRAS-regulated metabolic pathway. Nature 2013; 496: 101-105.
112. Greenhill C. Novel pathway identified for glutamine metabolism in PDAC. Nat Rev Gastroenterol Hepatol 2013; 10: 260.
113. Clerc P, Bensaadi N, Pradel P, Estival A, Clemente F, Vaysse N. Lipid-dependent proliferation of pancreatic cancer cell lines. Cancer Res 1991; 51: 3633-3638.
114. Calderon P, Furnelle J, Christophe J. In vitro lipid metabolism in the rat pancreas. I. Basal lipid metabolism. Biochim Biophys Acta 1979; 574: 379-390.
115. Berridge MJ. Inositol trisphosphate and diacylglycerol: Two interacting second messengers. Annu Rev Biochem 1987; 56: 159-193.
116. Ohmura E, Okada M, Onoda N, Kamiya Y, Murakami H, Tsushima T et al. Insulin-like growth factor I and transforming growth factor alpha as autocrine growth factors in human pancreatic cancer cell growth. Cancer Res 1990; 50: 103-107.
117. Liehr RM, Melnykovych G, Solomon TE. Growth effects of regulatory peptides on human pancreatic cancer lines PANC-1 and MIA PaCa-2. Gastroenterology 1990; 98: 1666-1674.
118. Smith JJ, Derynck R, Korc M. Production of transforming growth factor alpha in human pancreatic cancer cells: Evidence for a superagonist autocrine cycle. Proc Natl Acad Sci USA 1987; 84: 7567-7570.
119. Imagawa W, Bandyopadhyay GK, Wallace D, Nandi S. Phospholipids containing polyunsaturated fatty acyl groups are mitogenic for normal mouse mammary epithelial cells in serum-free primary cell culture. Proc Natl Acad Sci USA 1989; 86: 4122-4126.
120. Cheon EC, Strouch MJ, Barron MR, Ding Y, Melstrom LG, Krantz SB et al. Alteration of strain background and a high omega-6 fat diet induces earlier onset of pancreatic neoplasia in EL-Kras transgenic mice. Int J Cancer 2011; 128: 2783-2792.
121. Boudreau MD, Sohn KH, Rhee SH, Lee SW, Hunt JD, Hwang DH. Suppression of tumor cell growth both in nude mice and in culture by n-3 polyunsaturated fatty acids: Mediation through cyclooxygenase-independent pathways. Cancer Res 2001; 61: 1386-1391.
122. Khasawneh J, Schulz MD, Walch A, Rozman J, Hrabe de Angelis M, Klingenspor M et al. Inflammation and mitochondrial fatty acid beta-oxidation link obesity to early tumor promotion. Proc Natl Acad Sci USA 2009; 106: 3354-3359.
123. Calle EE, Rodriguez C, Walker-Thurmond K, Thun MJ. Overweight, obesity, and mortality from cancer in a prospectively studied cohort of U.S. adults. N Engl J Med 2003; 348: 1625-1638.
124. Michaud DS, Giovannucci E, Willett WC, Colditz GA, Stampfer MJ, Fuchs CS. Physical activity, obesity, height, and the risk of pancreatic cancer. JAMA 2001; 286: 921-929.
125. Rose DP. Effects of dietary fatty acids on breast and prostate cancers: Evidence from in vitro experiments and animal studies. Am J Clin Nutr 1997; 66(6 Suppl): 1513S-1522S.
126. Rose DP, Connolly JM. Dietary fat and breast cancer metastasis by human tumor xenografts. Breast Cancer Res Treat 1997; 46: 225-237.
127. Rose DP, Connolly JM. Omega-3 fatty acids as cancer chemopreventive agents. Pharmacol Ther 1999; 83: 217-244.
128. Strouch MJ, Ding Y, Salabat MR, Melstrom LG, Adrian K, Quinn C et al. A high omega-3 fatty acid diet mitigates murine pancreatic precancer development. J Surg Res 2011; 165: 75-81.
129. Farre JC, Krick R, Subramani S, Thumm M. Turnover of organelles by autophagy in yeast. Curr Opin Cell Biol 2009; 21: 522-530.
130. Yang Z, Klionsky DJ. Mammalian autophagy: Core molecular machinery and signaling regulation. Curr Opin Cell Biol 2010; 22: 124-131.
131. Ganley IG, Lam du H, Wang J, Ding X, Chen S, Jiang X. ULK1.ATG13.FIP200 complex mediates mTOR signaling and is essential for autophagy. J Biol Chem 2009; 284: 12297-12305.
132. Jung CH, Jun CB, Ro SH, Kim YM, Otto NM, Cao J et al. ULK-Atg13-FIP200 complexes mediate mTOR signaling to the autophagy machinery. Mol Biol Cell 2009; 20: 1992-2003.
133. Mercer CA, Kaliappan A, Dennis PB. A novel, human Atg13 binding protein, Atg101, interacts with ULK1 and is essential for macroautophagy. Autophagy 2009; 5: 649-662.
134. Reggiori F, Klionsky DJ. Autophagosomes: Biogenesis from scratch? Curr Opin Cell Biol 2005; 17: 415-422.
135. Suzuki K, Ohsumi Y. Molecular machinery of autophagosome formation in yeast, Saccharomyces cerevisiae. FEBS Lett 2007; 581: 2156-2161.
136. Hosokawa N, Hara T, Kaizuka T, Kishi C, Takamura A, Miura Y et al. Nutrient-dependent mTORC1 association with the ULK1-Atg13-FIP200 complex required for autophagy. Mol Biol Cell 2009; 20: 1981-1991.
137. Wirawan E, Vanden Berghe T, Lippens S, Agostinis P, Vandenabeele P. Autophagy: For better or for worse. Cell Res 2012; 22: 43-61.
138. Mizushima N, Kuma A, Kobayashi Y, Yamamoto A, Matsubae M, Takao T et al. Mouse Apg16L, a novel WD-repeat protein, targets to the autophagic isolation membrane with the Apg12-Apg5 conjugate. J Cell Sci 2003; 116(Pt 9): 1679-1688.
139. Kabeya Y, Mizushima N, Yamamoto A, Oshitani-Okamoto S, Ohsumi Y, Yoshimori T. LC3, GABARAP and GATE16 localize to autophagosomal membrane depending on form-II formation. J Cell Sci 2004; 117(Pt 13): 2805-2812.
140. Liang XH, Jackson S, Seaman M, Brown K, Kempkes B, Hibshoosh H et al. Induction of autophagy and inhibition of tumorigenesis by beclin 1. Nature 1999; 402: 672-676.
141. Yazbeck VY, Buglio D, Georgakis GV, Li Y, Iwado E, Romaguera JE et al. Temsirolimus downregulates p21 without altering cyclin D1 expression and induces autophagy and synergizes with vorinostat in mantle cell lymphoma. Exp Hematol 2008; 36: 443-450.
142. Ertmer A, Huber V, Gilch S, Yoshimori T, Erfle V, Duyster J et al. The anticancer drug imatinib induces cellular autophagy. Leukemia 2007; 21: 936-942.
143. Gorzalczany Y, Gilad Y, Amihai D, Hammel I, Sagi-Eisenberg R, Merimsky O. Combining an EGFR directed tyrosine kinase inhibitor with autophagy-inducing drugs: A beneficial strategy to combat non-small cell lung cancer. Cancer Lett 2011; 310: 207-215.
144. Hsu KF, Wu CL, Huang SC, Wu CM, Hsiao JR, Yo YT et al. Cathepsin L mediates resveratrol-induced autophagy and apoptotic cell death in cervical cancer cells. Autophagy 2009; 5: 451-460.
145. Rez G, Toth S, Palfia Z. Cellular autophagic capacity is highly increased in azaserineinduced premalignant atypical acinar nodule cells. Carcinogenesis 1999; 20: 1893-1898.
146. Yang S, Wang X, Contino G, Liesa M, Sahin E, Ying H et al. Pancreatic cancers require autophagy for tumor growth. Genes Dev 2011; 25: 717-729.
147. Fujii S, Mitsunaga S, Yamazaki M, Hasebe T, Ishii G, Kojima M et al. Autophagy is activated in pancreatic cancer cells and correlates with poor patient outcome. Cancer Sci 2008; 99: 1813-1819.
148. Guo JY, Chen HY, Mathew R, Fan J, Strohecker AM, Karsli-Uzunbas G et al. Activated Ras requires autophagy to maintain oxidative metabolism and tumorigenesis. Genes Dev 2011; 25: 460-470.
149. Mazure NM, Pouyssegur J. Hypoxia-induced autophagy: Cell death or cell survival? Curr Opin Cell Biol 2010; 22: 177-180.
150. Tracy K, Dibling BC, Spike BT, Knabb JR, Schumacker P, Macleod KF. BNIP3 is an RB/E2F target gene required for hypoxia-induced autophagy. Mol Cell Biol 2007; 27: 6229-6242.
151. Pattingre S, Tassa A, Qu X, Garuti R, Liang XH, Mizushima N et al. Bcl-2 antiapoptotic proteins inhibit Beclin 1-dependent autophagy. Cell 2005; 122: 927-939.
152. Okami J, Simeone DM, Logsdon CD. Silencing of the hypoxia-inducible cell death protein BNIP3 in pancreatic cancer. Cancer Res 2004; 64: 5338-5346.
153. Neeper M, Schmidt AM, Brett J, Yan SD, Wang F, Pan YC et al. Cloning and expression of a cell surface receptor for advanced glycosylation end products of proteins. J Biol Chem 1992; 267: 14998-15004.
154. Bucciarelli LG, Wendt T, Rong L, Lalla E, Hofmann MA, Goova MT et al. RAGE is a multiligand receptor of the immunoglobulin superfamily: Implications for homeostasis and chronic disease. Cell Mol Life Sci 2002; 59: 1117-1128.
155. Basta G, Lazzerini G, Del Turco S, Ratto GM, Schmidt AM, De Caterina R. At least 2 distinct pathways generating reactive oxygen species mediate vascular cell adhesion molecule-1 induction by advanced glycation end products. Arterioscler Thromb Vasc Biol 2005; 25: 1401-1407.
156. Cai W, He JC, Zhu L, Lu C, Vlassara H. Advanced glycation end product (AGE) receptor 1 suppresses cell oxidant stress and activation signaling via EGF receptor. Proc Natl Acad Sci USA 2006; 103: 13801-13806.
157. Alexiou P, Chatzopoulou M, Pegklidou K, Demopoulos VJ. RAGE: A multi-ligand receptor unveiling novel insights in health and disease. Curr Med Chem 2010; 17: 2232-2252.
158. Rojas A, Figueroa H, Morales E. Fueling inflammation at tumor microenvironment: The role of multiligand/RAGE axis. Carcinogenesis 2010; 31: 334-341.
159. Logsdon CD, Fuentes MK, Huang EH, Arumugam T. RAGE and RAGE ligands in cancer. Curr Mol Med 2007; 7: 777-789.
160. Abe R, Yamagishi S. AGE-RAGE system and carcinogenesis. Curr Pharm Des 2008; 14: 940-945.
161. Kang R, Tang D, Schapiro NE, Livesey KM, Farkas A, Loughran P et al. The receptor for advanced glycation end products (RAGE) sustains autophagy and limits apoptosis, promoting pancreatic tumor cell survival. Cell Death Differ 2010; 17: 666-676.
162. Hori O, Brett J, Slattery T, Cao R, Zhang J, Chen JX et al. The receptor for advanced glycation end products (RAGE) is a cellular binding site for amphoterin. Mediation of neurite outgrowth and co-expression of rage and amphoterin in the developing nervous system. J Biol Chem 1995; 270: 25752-25761.
163. Tang D, Kang R, Zeh 3rd HJ, Lotze MT. High-mobility group box 1 and cancer. Biochim Biophys Acta 2010; 1799: 131-140.
164. Liu Y, Prasad R, Wilson SH. HMGB1: Roles in base excision repair and related function. Biochim Biophys Acta 2010; 1799: 119-130.
165. Kang R, Tang D, Livesey KM, Schapiro NE, Lotze MT, Zeh 3rd HJ. The receptor for advanced glycation end-products (RAGE) protects pancreatic tumor cells against oxidative injury. Antioxid Redox Signal 2011; 15: 2175-2184.
166. Kang R, Tang D, Schapiro NE, Loux T, Livesey KM, Billiar TR et al. The HMGB1/RAGE inflammatory pathway promotes pancreatic tumor growth by regulating mitochondrial bioenergetics. Oncogene 2013; 33: 567-577.
167. Tang D, Kang R, Livesey KM, Cheh CW, Farkas A, Loughran P et al. Endogenous HMGB1 regulates autophagy. J Cell Biol 2010; 190: 881-892.
168. Kim MJ, Woo SJ, Yoon CH, Lee JS, An S, Choi YH et al. Involvement of autophagy in oncogenic K-Ras-induced malignant cell transformation. J Biol Chem 2011; 286: 12924-12932.
169. Lock R, Roy S, Kenific CM, Su JS, Salas E, Ronen SM et al. Autophagy facilitates glycolysis during Ras-mediated oncogenic transformation. Mol Biol Cell 2011; 22: 165-178.
170. Mancias JD, Kimmelman AC. Targeting autophagy addiction in cancer. Oncotarget 2011; 2: 1302-1306.